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doi:10.1016/j.jtcvs.2004.02.007588 The Journal of Thoracic and CardioObjective: During myocardial ischemia-reperfusion injury, p38 mitogen-activated
protein kinase is activated. We examined the effect of a highly specific inhibitor of
p38 mitogen-activated protein kinase, FR167653, in an experimental model of
regional myocardial ischemia-reperfusion.
Methods: CD-1 mice received FR167653 intraperitoneally 24 hours before 30
minutes of transient occlusion of the left anterior descending artery, followed by 120
minutes of reperfusion. The p38 mitogen-activated protein kinase activation and
kinase activity were determined by Western blotting with monoclonal antibodies for
the phosphorylated from of p38 mitogen-activated protein kinase or its substrate,
activating transcription factor 2. Nuclear factor B activity was measured by
detecting translocation of nuclear factor B to the nucleus. The expression of
inflammatory cytokines was measured by ribonuclease protection assay.
Results: Pretreatment of mice with FR167653 before myocardial ischemia-reperfu-
sion resulted in a reduction in p38 mitogen-activated protein kinase phosphorylation
(P  .018), an inhibition of p38 mitogen-activated protein kinase activity (P 
.047), a smaller amount of nuclear factor B (P  .001), and a decrease in the
expression of inflammatory cytokines (tumor necrosis factor : P  .023, interleu-
kin 1: P  .038, monocyte chemotactic protein 1: P  .0001) in the heart and the
development of a significantly smaller infarct (P  .0069) relative to hearts from
mice treated with vehicle alone. Activation of c-Jun N-terminal kinase and extra-
cellular signal–regulated kinase were observed after myocardial ischemia-reperfu-
sion without inhibition by FR167653.
Conclusion: We conclude that FR167653 selectively inhibits p38 mitogen-activated
protein kinase activation and activity during regional myocardial ischemia-reperfu-
sion injury and efficaciously reduces infarct size (by 73.6%). Thus p38 mitogen-
activated protein kinase inhibition may have a role in the treatment of myocardial
ischemia-reperfusion.
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PMyocardial ischemia-reperfusion injuryis a major risk factor for patients un-dergoing treatment for cardiac dis-ease, including percutaneous coro-nary angioplasty, coronary arterybypass grafting, heart and lung trans-
plantation, and other cardiac procedures that require cardio-
pulmonary bypass.1-4 Although the pathophysiology of
myocardial ischemia-reperfusion injury remains largely un-
known, activation of mitogen-activated protein kinases
(MAPKs), including p38 MAPK, c-Jun N-terminal kinase
(JNK), and extracellular signal–regulated kinase (ERK), are
early events. Both p38 MAPK and JNK are associated with
cellular responses to stress, whereas ERK activity is asso-
ciated with growth and development processes in the cell.
Once activated, the MAPKs phosphorylate and activate
other intracellular mediators, resulting in the transcription
of genes that encode such proteins as adhesion molecules,
proinflammatory mediators, procoagulant molecules, and
vasoactive substances.5-10 This sequence of events may
progress to irreversible tissue injury caused by an acute
inflammatory response.11-14
Recently, FR167653* has been shown to be a specific
p38 MAPK inhibitor without affecting cyclooxygenase
(COX) or other MAPKs.15 It competes with adenosine
triphosphate (ATP) at the ATP-binding site of only p38
MAPK.15
We hypothesize that myocardial ischemia-reperfusion
stress activates MAPKs, with subsequent activation of nu-
clear factor (NF) B, resulting in enhanced cytokine expres-
sion associated with myocardial ischemia-reperfusion in-
jury. Further, we postulate that specific inhibition of p38
MAPK with FR167653 will attenuate myocardial ischemia-
reperfusion injury through inhibition of NF-B. In this
study, we evaluated the effect of FR167653 on myocardial
ischemia-reperfusion injury in mice.
Materials and Methods
Animals and Experimental Design
Male CD-1 mice weighing 20 to 25 g (Charles River Laboratory,
Inc, Wilmington, Mass) were divided into three groups: (1) the
FR167653 group in which 200 L of FR167653 (2 mg/kg dis-
solved in saline solution; Fujisawa Pharmaceutical Co, Ltd, Osaka,
Japan) was administered intraperitoneally 24 hours before 30
minutes of ischemia followed by 120 minutes of reperfusion, (2) a
vehicle group in which 200 L of saline solution was administered
intraperitoneally 24 hours before myocardial ischemia-reperfusion,
and (3) a control group in which 200 L of saline solution was
administered intraperitoneally 24 hours before sham operation.
A mouse model of in situ regional myocardial ischemia-reper-
fusion was used as previously described elsewhere.16 In brief, the
mice were intubated and placed under mechanical ventilation after
*1-[7-(4-fluorophenyl)-1,2,3,4-tetrahydro-8 (4-pyridyl) pyrazoro (5-1-
c)(1,2,4) triazin-2-yl]–2-phenylethanedione sulfate monohydrate.
The Journal of Thoraciundergoing general anesthesia with pentobarbital sodium (100
mg/kg, intramuscularly). A lateral thoracotomy was performed to
expose hearts, and myocardial ischemia was produced by ligating
the left anterior descending coronary artery (LAD) with a 7-0 silk
suture. After 30 minutes of ischemia, the occlusive snare was
released to initiate reperfusion for 120 minutes. Sham-operated
control mice underwent the same surgical procedures except that
the suture that was passed under the LAD was not tied. Molecular
analysis end points were as follows: 5 minutes of reperfusion for
MAPK activation, p38 MAPK activity and IB phosphorylation;
60 minutes of reperfusion for NF-B activity; and at the comple-
tion of reperfusion for messenger RNA (mRNA) to assess cytokine
expression. Hearts were rapidly explanted and the left ventricle
was dissected free, rinsed in 0.9% saline solution, snap-frozen in
liquid nitrogen, and then stored at 80°C until subsequent anal-
ysis, whereas area at risk and infarct size were determined at the
completion of reperfusion as previously described elsewhere.16
All animals were maintained in accordance with the “Guide for
the Care and Use of Laboratory Animals” (http://www.nap.edu/
catalog/5140.html) and also with the Guideline of the Animal Care
and Use Committee of the University of Washington.
Western Blotting Assay for Phosphorylation of
MAPKs and IB
Whole-cell protein, extracted from frozen tissue samples with
ice-cold lysis buffer (Cell Signaling Technology, Inc, Beverly,
Mass), were stored at 80°C until the time of assay. A 20-g
portion of whole-cell protein was loaded onto 15% dodecylsulfate-
polyacrylamide electrophoretic gels and transferred to polyvinyli-
dene difluoride membranes. The membranes were immunoblotted
with primary antibodies in PhosphoPlus p38 MAPK (Thr180/
Tyr182), JNK (Thr180/Tyr182), ERK (Thr180/Tyr182), and IB
(Ser32) Antibody Kits (1:1000; Cell Signaling Technology). Im-
munoreactivity was quantitated with enhanced chemiluminescence
and determined with densitometry (NIH Image 1.62; National
Institutes of Health, Bethesda, Md). The ratio of phospho-MAPK
to total MAPK, or phospho-IB, immunoreactivity was deter-
mined for each sample, and the results are expressed as fold-
increase with respect to control.
p38 MAPK Activity Assay
The p38 MAPK activity was measured with the p38 MAPK Assay
Kit (Cell Signaling Technology) combining immunoprecipitation,
kinase assay, and immunoblotting. The results are shown as the
immunoreactivity of phosphorylated activating transcription factor
(ATF) 2 (Thr71), detected with enhanced chemiluminescence and
determined with densitometry (NIH Image 1.62). Results are ex-
pressed as multiples of increase in activation with respect to
control.
Electrophoretic Mobility Shift Assays for NF-B
Activity
Myocardial nuclear proteins from frozen tissue samples were iso-
lated as previously described.16 A 10-g portion of nuclear protein
was incubated in a binding reaction with a 32P–end-labeled, dou-
ble-stranded oligonucleotide containing the human and rodent
consensus NF-B binding sequence, 5’-AGTTGAGGGGACTT-
TCCCAGGC-3’ (Promega Co, Madison, Wis) and subjected to
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Densitometry was performed with NIH Image 1.62. Results are
expressed as fold-increase in activation with respect to control.
Ribonuclease Protection Assay
Total RNA was isolated from frozen tissue samples by guanidium
thiocyanate-phenol-chloroform method. RNA from each tissue
was evaluated with RPA III Ribonuclease Protection Assay Kit
(Ambion, Inc, Austin, Tex) and customized mouse cytokines tem-
plate (Riboquant Multi-Probe Template Set; BD Biosciences
Pharmingen, San Diego, Calif) according to the manufacturer’s
protocol. Densitometric analysis was done with NIH Image 1.62.
Results are expressed as multiples of increase with respect to
control after the amount of mRNA for each cytokine was normal-
ized to glyceraldehyde-3-phosphate dehydrogenase mRNA.
Statistical Analysis
All data are expressed as mean  SD. The significance of the
difference between group means was analyzed by analysis of
variance with post hoc comparisons by Scheffe´ protected least-
significant difference test. All statistical analyses were done with
StatView 6.0 software (SAS Institute, Inc, Cary, NC).
Results
Effect of p38 MAPK Inhibition on Myocardial Infarct
Size After Ischemia-Reperfusion
The ratio of area at risk to left ventricle did not differ
between vehicle-treated and FR167653-treated groups. Pre-
treatment with FR167653 significantly reduced infarct size
Figure 1. FR167653 blocks myocardial ischemia-reperfusion. CD-1
mice were subjected to myocardial ischemia-reperfusion injury,
and area at risk (AAR) as a percentage of left ventricle (LV) and
infarct size as a percentage of area at risk were determined as
described in Materials and Methods section for control mice that
received vehicle alone (cross-hatched bars) or vehicle with
FR167653 (FR, 2 mg/kg, black bars). Values represent mean  SD
of 5 animals; asterisk indicates P < .01 versus vehicle.within the area at risk by 73.6% relative to vehicle pretreat-
590 The Journal of Thoracic and Cardiovascular Surgery ● Octoment (FR167653 vs vehicle: 11.4%  6.8% vs 43.2% 
3.3%, P  .0069; Figure 1).
Myocardial MAPK Activation After Ischemia-
Reperfusion
Phosphorylation of JNK was significantly increased in both
groups after myocardial ischemia-reperfusion compared
with the control group (FR167653: 6.97  1.38-fold in-
crease, P  .001, vehicle: 6.39  1.08-fold increase, P 
.001); there was no significant difference between
FR167653 and vehicle groups. Phosphorylation of ERK
was also significantly increased in both groups after myo-
cardial ischemia-reperfusion relative to the control group
(FR167653: 2.48  1.28-fold increase, P  .001, vehicle:
2.50  1.08-fold increase, P  .001), and there was no
difference between those that received FR167653 pretreat-
ment versus pretreatment with vehicle. Myocardial isch-
Figure 2. Effects of FR167653 (FR) on myocardial MAPK activation
after ischemia-reperfusion. Western blotting analyses of phos-
pho-JNK and total JNK (A), ERK (B), and p38 MAPK (C) expres-
sions. D, Phosphorylation of MAPKs. Values represent mean 
SD of 5 animals; asterisk indicates P < .001 versus control;
dagger indicates P < .05 versus vehicle.emia-reperfusion significantly increased phospho-p38
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PMAPK relative to control (FR167653: 5.68  1.46-fold
increase, P  .001, vehicle: 10.17  2.77-fold increase, P
 .001). In contrast to JNK and ERK activation, FR167653
pretreatment significantly reduced the activation of p38
MAPK (P  .018 vs vehicle; Figure 2). Myocardial isch-
emia-reperfusion also significantly increased p38 MAPK
activity, which was measured directly by detecting phos-
phorylation of a p38 MAPK substrate, ATF-2, in both
groups relative to the control group (FR167653: 6.51 
3.36-fold increase, P  .001, vehicle: 9.74  3.56-fold
increase, P  .001). Pretreatment of mice with FR167653
before myocardial ischemia-reperfusion, however, signifi-
cantly attenuated p38 MAPK activity relative to vehicle-
treated animals (P  .047, Figure 3).
Effect of p38 MAPK Inhibition on Myocardial NF-B
Activation After Ischemia-Reperfusion
Relative to the control group, in vehicle-pretreated animals,
there was a significant rise in NF-B activation, as deter-
mined by assay of NF-B translocation to the nuclear frac-
tion (2.00  0.20-fold increase, P  .001). Pretreatment
with FR167653, however, abrogated this activation (1.18 
0.12-fold increase, P .001 vs vehicle). Phosphorylation of
IB, which is required for NF-B activation, was signif-
icantly suppressed by FR167653, consistent with inhibition
by FR167653 of p38 MAPK-mediated NF-B activation
(FR167653: 0.98 0.23-fold increase, P .028 vs vehicle,
vehicle: 3.99  2.01-fold increase, P  .05 vs control;
Figure 3. Effects of FR167653 (FR) on myocardial p38 MAPK ac-
tivity after ischemia-reperfusion. A, Western blotting analysis of
phospho-ATF-2 expression after immunoprecipitation and kinase
assay for p38 MAPK activity. B, p38 MAPK activities. Values
represent mean  SD of 5 animals; asterisk indicates P < .001
versus control; dagger indicates P < .05 versus vehicle.Figure 4).
The Journal of ThoraciEffect of p38 MAPK Inhibition on Myocardial
Inflammatory Cytokine Gene Expression After
Ischemia-Reperfusion
Myocardial ischemia-reperfusion stress significantly in-
creased mRNA levels of tumor necrosis factor (TNF) ,
interleukin (IL) 1, and monocyte chemotactic protein
(MCP) 1 in vehicle-pretreated mice (TNF-: 1.56  0.27-
fold increase, P  .05 vs control, IL-1: 3.46  1.14-fold
increase, P  .01 vs control, MCP-1: 7.46  0.48-fold
increase, P .001 vs control). Pretreatment with FR167653
significantly attenuated this inflammatory cytokine response
(TNF-: 0.65  0.18-fold increase, P  .023 vs vehicle,
IL-1: 1.57  0.14-fold increase, P  .038 vs vehicle,
MCP-1: 2.84  0.77-fold increase, P  .00015 vs vehicle;
Figure 5). FR167653 had no effect on expression of lym-
photactin; macrophage inflammatory protein 1, 1, and 2;
RANTES (regulated on activation, normal T-cell expressed
and secreted), T-cell activation gene 3, or eotaxin (data not
shown).
Discussion
This study demonstrates that myocardial ischemia-reperfu-
sion injury in a mouse model causes rapid phosphorylation
and activation of p38 MAPK and JNK, subsequent NF-B
activation, cytokine expression in the ischemia-reperfusion-
injured myocardium, and ultimately infarction. A limitation
Figure 4. Effects of p38 MAPK inhibition by FR167653 (FR) on
myocardial NF-B activation after ischemia-reperfusion. A, Elec-
trophoretic mobility shift assay of NF-B activation. B, Western
blotting analysis of phospho-IB expression as indirect indica-
tor of NF-B activation. C, NF-B activities and phosphorylation
of IB. Values represent mean  SD of 5 animals; asterisk
indicates P < .001 versus control; dagger indicates P < .05
versus vehicle.of this study is that we measured only myocardial infarction
c and Cardiovascular Surgery ● Volume 128, Number 4 591
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Although possible to a limited degree in mice, acquisition of
myocardial functional data is exceedingly difficult and po-
tentially unreliable. We therefore relied on infarct size as
our end point measurement of regional myocardial isch-
emia-reperfusion injury. These cellular events, with the
exception of JNK and ERK activation, were suppressed by
pretreatment of mice with FR167653, which specifically
blocks p38 MAPK activation by competing with ATP at the
ATP-binding site of only p38 MAPK.
Previous studies have used SB203580 as a p38 MAPK
inhibitor.17-19 The actions of SB203580, however, are not
confined to selective inhibition of p38 MAPK. SB203580
has been reported to inhibit thromboxane synthase, COX-1
and -2,20 and JNK,21 all of which may directly affect injury
Figure 5. Effects of p38 MAPK inhibition by FR167653 (FR) on
myocardial inflammatory cytokine gene expression after isch-
emia-reperfusion. A, Ribonuclease protection assay of TNF-,
IL-1, MCP-1, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, internal control) mRNA expressions. B, Vertical axis
denotes multiplicity of increase relative to control after amount of
mRNA for each cytokine was normalized to that of glyceralde-
hyde-3-phosphate dehydrogenase mRNA. Values represent mean
 SD of 5 animals; asterisk indicates P < .05 versus control;
dagger indicates P < .05 versus vehicle.after myocardial ischemia-reperfusion. This nonspecific ac-
592 The Journal of Thoracic and Cardiovascular Surgery ● Octotion of SB203580 may be the reason for the conflicting
observations that have been reported regarding the role of
p38 MAPK in myocardial ischemia-reperfusion injury.
The p38 subfamily of MAPKs consists of four isoforms
(, , , and ); only p38 and p38 have been detected in
the cardiac tissue.22 MAPK kinases (MKKs) selectively
activate p38 MAPK in different cell types and exhibit
isoform specificity: MKK3 activates only  and  isoforms,
whereas MKK6 can activate , , and  isoforms.22 Recent
studies revealed a different role for p38 and  isoforms in
apoptotic responses and cell survival: a negative role for
p38 and positive role for p38.10,23 One possible expla-
nation for these divergent functions of p38 MAPK isoforms
is that they mediate phosphorylation of different down-
stream substrates that have different roles in apoptosis.
Ischemia-reperfusion and ischemic preconditioning may
differentially activate p38 MAPK isoforms, accounting for
the controversies in previous studies. Ischemia-reperfusion
has been shown to activate p38.5,24,25 Myocytes that ec-
topically expressed p38 and p38 showed activation of
p38 during sustained simulated ischemia, whereas the
p38 isoform was deactivated.26 Moreover, in rat heart cells
expressing wild-type p38, injury was reduced by p38
MAPK inhibition, suggesting that the selective inhibition of
the p38 isoform of the p38 MAPK pathway may underlie
the mechanism responsible for anti-ischemic effects ob-
served after p38 MAPK inhibition.10 The p38 isoform
appears to play a positive role in the protection against
apoptotic cell death.23
FR167653 is a specific inhibitor for p38 MAPK; it in-
hibits p38 strongly but not specifically.15 In our study,
however, FR167653 significantly suppressed phosphoryla-
tion of both the  and  p38 isoforms. Some studies have
reported that p38 is mainly phosphorylated under pro-
longed ischemia and reperfusion conditions, such as our
model; however p38 has been phosphorylated in transient
ischemia, including ischemic preconditioning.23,26-28 This
shows that a specific p38 MAPK inhibitor, although not
specific for the p38 isoform, was effective in prevent
myocardial ischemia-reperfusion injury.29
Myocardial ischemia-reperfusion injury is thought to re-
sult from an intense local inflammatory response involving
cellular (neutrophil, endothelial cell, and monocyte) activa-
tion and elaboration of inflammatory mediators including
cytokines, chemokines, and adhesion molecules. These in-
flammatory mediators in turn are capable of further activat-
ing multiple cell types and thus propagating an inflamma-
tory response. Our results indicate that in murine hearts
subjected to ischemia-reperfusion, MAPKs and inflamma-
tory transcription factors become activated, resulting in
elaboration of multiple inflammatory mediators and myo-
cardial tissue destruction. NF-B promotes transcription of
many genes that encode proteins involved in inflammation.
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PNF-B activation is involved in myocardial ischemia-reper-
fusion injury and also ischemic preconditioning.30 How-
ever, these previous results may not be directly extrapolated
to the entire pathway in myocardial ischemia-reperfusion
injury, particularly between MAPKs and NF-B, and there-
fore the roles of cardiac MAPKs remain to be elucidated in
these clinically relevant pathophysiologic conditions. Proin-
flammatory mediators correlated with myocardial ischemia-
reperfusion, such as inflammatory cytokines, chemokines,
and some growth factors, have been shown to activate
MAPK pathways.31 In addition, TNF- and IL-1 can be
generated by p38 MAPK–dependent pathways.32 The focus
of our study was on evaluation of p38 MAPK as a possible
therapeutic target to minimize myocardial ischemia-reper-
fusion injury.
Ischemic heart disease and acute myocardial infarction
represent a major therapeutic challenge. Mammalian cells
respond to ischemia with activation of numerous cell-sig-
naling cascades that can eventually lead to irreversible
damage of the myocardium and cell death. Our studies have
found that ischemia-reperfusion induce distinct regulation
of specific MAPK cascades, with noted differences in the
intensity and time course of their activation, as well as
interspecies differences.33 Activation of multiple parallel
MAPK pathways may be important in the heart’s response
to cellular stress.5 In this study, increased phosphorylations
of p38 MAPK, JNK, and ERK were confirmed immediately
after reperfusion.
We have previously evaluated the toxicity of long-term
treatment in a murine model of FR167653 (2 and 10 mg/
[kg · d] intramuscularly) daily for 18 weeks by measure-
ment of serum levels of glutamic oxaloacetic transami-
nase, glutamic pyruvate transaminase, creatine kinase,
alkaline phosphatase, blood urea nitrogen, and creatinine
along with histopathologic assessment of brain, heart,
lung, liver, and kidney. There were no abnormalities in
any of these parameters at the completion of the 18-week
study (data not shown). Because of the potential clinical
applicability suggested by our results, additional pharma-
cologic studies will be important.
In conclusion, we have shown in a mouse model that
myocardial ischemia-reperfusion causes rapid phosphoryla-
tion and activation of MAPKs, with subsequent NF-B
activation, which results in cytokine expression and myo-
cardial ischemia-reperfusion injury. Pretreatment with
FR167653, which specifically and potently inhibits p38
MAPK, reduces NF-B activation and inflammatory cyto-
kine expression, decreasing myocardial tissue injury. These
data show that p38 MAPK plays a central role in the
molecular events that underlie myocardial ischemia-reper-
fusion injury. Accordingly, inhibition of p38 MAPK activ-
ity may be a therapeutic target in the prevention of inflam-
matory cytokine mediated tissue destruction seen with such
The Journal of Thoracihyperinflammatory disorders as myocardial ischemia-reper-
fusion.
We thank Fujisawa Pharmaceutical Co, Ltd, for their generous
gift of FR167653.
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